Dry Eye Disease (DED)
Conditions
Keywords
DED, TRYPTYR
Brief summary
The purpose of this research study is to determine the effectiveness of TRYPTYR as a treatment for Dry Eye Disease. The primary efficacy variable is change from baseline in the Ocular Surface Disease Index (OSDI) at week 2. The co-primary efficacy variables are change from baseline in the National Eye Institute (NEI) scale of the cornea and NEI scale of the conjunctiva at 1 month (the third visit).
Interventions
TRYPTYR will be administered one drop in each eye twice daily (once every 12 hours) for 30 days.
Sponsors
NYU Langone Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adults (18 and older) 2. Ability to provide informed consent and to understand the study procedures 3. Patients diagnosed with dry eye disease 4. Presence of dry eye symptoms determined by a validated questionnaire (OSDI- Attachment 1) with scores above a specified threshold AND 5. Tear film break-up time (TBUT) below a set value (less than 8 seconds) 6. Schirmer test (w/o drops) value below a set cut-off (less than 10 mm) 7. Positive findings on ocular surface staining (NEI \>/equal 3) 8. Positive conjunctival staining (NEI \>4) 9. Moderate meibomian gland dysfunction (MGD)
Exclusion criteria
* History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, interfere with the interpretation of the study results or subject safety * History of ocular surgery within 3 months prior to the Screening visit, including punctal cautery, corneal refractive, or anterior segment surgeries that affect corneal sensitivity (e.g., cataract surgery or any surgery involving limbal or corneal incision) or lid surgery * Have had a corneal transplant in either or both eyes * Patients with current steroid use * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in ocular surface disease index (OSDI) Score | Baseline, Week 2 | The Ocular Surface Disease Index (OSDI) is a 12-question screening tool used to measure the severity of dry eye disease and how it affects vision. Scores range from 0 to 100, with higher numbers indicating more severe symptoms. |
| Change in National Eye Institute (NEI) scale of the cornea | Baseline, 1 Month | The NEI scale of the cornea is a standardized system used to grade corneal fluorescein staining. It evaluates punctate epithelial erosions (staining) across five specific corneal zones (superior, inferior, nasal, temporal, and central) to yield a total severity score. Each of the 5 zones is graded on an integer scale from 0 (No staining) to 3 (Severe or confluent staining). Total scores of 0-5 typically indicate mild surface disease, 6-10 represent moderate disease, and 11-15 indicate severe ocular surface disease. |
| Change in NEI scale of the conjunctiva | Baseline, 1 Month | The National Eye Institute (NEI) scale of the conjunctiva evaluates the ocular surface by dividing the conjunctiva into six specific areas for evaluation to grade staining. Each of these six regions is graded individually on a 0 (none) to 3 (severe) scale. By adding the scores of all six regions, the conjunctiva yields a total score ranging from 0 to 18. Low scores represent a healthy or mildly compromised ocular surface, whereas high scores indicate severe surface disease like dry eye |
Countries
United States
Contacts
CONTACTJamika Singleton-Garvin
PRINCIPAL_INVESTIGATORGiacomina Massaro-Giordano, MD
NYU Langone Health
Outcome results
None listed